Project to Promote the Evaluation of the Cardiovascular Risk in the Clinical Practice and to Evaluate Its Evolution Following the Implementation of a Preventive Multifactorial Strategy Aimed to Reduce the Total Risk Level (SCORE Algorithm), in Subjects Suffering From Metabolic Syndrome and With a Risk Level greater than or equal to 5%.
Phase of Trial: Phase IV
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Fluvastatin; Hydrochlorothiazide; Valsartan
- Indications Cardiovascular disorders; Metabolic syndrome
- Focus Therapeutic Use
- Acronyms LesScore
- Sponsors Novartis
- 19 Jan 2009 New trial record.